Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
주식 순위 #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
주가
$3.12
시가총액
$294.21M
변동 (1일)
-3.26%
변동 (1년)
-51.10%
국가
US
거래 Myriad Genetics, Inc. (MYGN)

카테고리

B의 시가 총액을 가진 MYGN의 가격
Myriad Genetics, Inc. Myriad Genetics, Inc.
MYGN
$3.12
의 시가총액 Myriad Genetics, Inc.(MYGN)
시가총액: $294.21M
September 2026 기준으로 Myriad Genetics, Inc.의 시가총액은 $294.21M입니다. 이는 당사 데이터에 따르면 Myriad Genetics, Inc.이 세계에서 16435th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
1995부터 2026까지 Myriad Genetics, Inc.의 시가총액 기록
MYGN 가장 인기있는 상위 5 가지 stocks과 비교하여
MYGN의 가격 자산 b b의 시장 결과
Myriad Genetics, Inc. Myriad Genetics, Inc.
$55,687.76 $294.21M
$5.260T +1,787,629.19%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$50,594.20 $294.21M
$4.779T +1,624,111.81%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$42,528.50 $294.21M
$4.017T +1,365,181.01%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$39,379.35 $294.21M
$3.719T +1,264,084.73%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$28,949.62 $294.21M
$2.734T +929,261.77%